Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 5/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911090 | 0.95 | RAD52 (0.43) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4911169 | 0.95 | RAD52 (0.43) | RAD52SMARCA2UHRF1PTK2MCHR1 | |
| SCHEMBL4911257 | 0.94 | RAD52 (0.46) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4906215 | 0.93 | RAD52 (0.51) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4913162 | 0.91 | PIM1 (0.38) | PTK2MAPT | |
| SCHEMBL4911007 | 0.91 | RAD52 (0.43) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4912215 | 0.90 | RAD52 (0.46) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4910606 | 0.89 | RAD52 (0.43) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4910435 | 0.89 | RAD52 (0.51) | RAD52SMARCA2UHRF1PTK2MAPT | |
| SCHEMBL4912292 | 0.89 | RAD52 (0.44) | RAD52SMARCA2UHRF1PTK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | RAD52 717/4885SMARCA2 3129/4885UHRF1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.